-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target

Benzinga·09/23/2026 12:29:58
Listen to the news
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.